Sensitive Thyrotropin and Thyrotropin-Receptor Antibody Determinations One Month After Discontinuation of Antithyroid Drug Treatment as Predictors of Relapse in Graves' Disease
Objective: After primary successful antithyroid drug treatment (ATDT), Graves' disease has a relapse rate of 30% to 50%. Previous studies have evaluated age, gender, goiter volume, smoking habits, and the presence of thyrotropin-receptor antibodies (TRAb) as predictive markers to facilitate an...
Gespeichert in:
Veröffentlicht in: | Thyroid (New York, N.Y.) N.Y.), 2005-09, Vol.15 (9), p.147-1054 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Objective:
After primary successful antithyroid drug treatment (ATDT), Graves' disease has a relapse rate of
30% to 50%. Previous studies have evaluated age, gender, goiter volume, smoking habits, and the presence of
thyrotropin-receptor antibodies (TRAb) as predictive markers to facilitate an individualized patient management.
Despite higher sensitivity and specificity of the new second generation human TSH-receptor assay, the
predictive value of TRAb for relapse of hyperthyroidism is still controversial. In a recent prospective multicenter
study we have previously shown that suppressed or low TSH values predict both early (persistence)
and late relapse of Graves' disease. We now present a more detailed analysis of the predictive value of TSH
and TRAb for recurrent hyperthyroidism.
Methods:
Four weeks after withdrawal of ATDT, 96 patients were
available for thyroid function tests, including a sensitive third-generation TSH assay and a second-generation
recombinant TSH receptor assay. Relapse of Graves' disease was evaluated for a total follow-up of 2 years.
Results:
Within 2 years, 47 of 96 patients (49%) developed relapse of hyperthyroidism. Nine patients relapsed
within the first 4 weeks after withdrawal of ATDT and were thus considered to have persistent Graves' disease.
Ten of 15 other patients with TSH levels below 0.3 mU/L without overt hyperthyroidism relapsed within
2 years. Twenty-five of 65 patients with normal TSH (0.3-3.0 mU/L) and 3 of 4 patients with TSH values above
3 mU/L also had recurrent hyperthyroidism. After ATDT cessation, TSH had a positive predictive value of
70% and a negative predictive value of 62% (specificity 85%) for relapse of Graves 'disease. Mean TRAb levels
in the group of patients with relapse were significantly higher (11.1 IU/L ± 0.17) than TRAb values in the remission
group (4.5 IU/L ± 0.6),
p
< 0.001. Using a cutoff value of 1.5 IU/L, TRAb had low positive and negative
predictive values of 49% and 54%, respectively (specificity, 14%), but with a cutoff level of 10 IU/L, predictive
values improved to 83% and 62%, respectively (specificity, 92%). Combination of TSH and TRAb
determinations did not further improve prediction of relapse. Other factors such as gender, age, goiter volume,
smoking habits, presence of thyroid-associated ophthalmopathy, and urinary iodine excreation did not show
a significant influence on relapse rate.
Conclusion:
Low TSH values 4 weeks after ATDT withdrawal predict relapse
of Graves' disease, |
---|---|
ISSN: | 1050-7256 1557-9077 |
DOI: | 10.1089/thy.2005.15.1047 |